Credit Suisse Group Reiterates GBX 1,300 Price Target for GlaxoSmithKline (GSK)
A number of other equities research analysts have also recently weighed in on GSK. Deutsche Bank restated a hold rating and set a GBX 1,610 ($22.57) price objective on shares of GlaxoSmithKline in a research note on Wednesday, October 11th. Jefferies Group upped their price objective on GlaxoSmithKline from GBX 1,675 ($23.49) to GBX 1,700 ($23.84) and gave the stock a buy rating in a research note on Monday, October 16th. Goldman Sachs Group restated a buy rating and set a GBX 1,900 ($26.64) price objective on shares of GlaxoSmithKline in a research note on Tuesday, October 17th. Morgan Stanley set a GBX 1,600 ($22.43) price target on GlaxoSmithKline and gave the company a sell rating in a research note on Wednesday, October 18th. Finally, Shore Capital reiterated a hold rating on shares of GlaxoSmithKline in a research note on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of Hold and a consensus price target of GBX 1,541.36 ($21.61).
Shares of GlaxoSmithKline (GSK) traded down GBX 12.80 ($0.18) during midday trading on Thursday, hitting GBX 1,291 ($18.10). The company had a trading volume of 11,683,099 shares, compared to its average volume of 9,220,000. The stock has a market cap of $64,010.00 and a PE ratio of 4,164.52. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($17.32) and a 1 year high of GBX 1,724.50 ($24.18).
In other news, insider Sir Roy Anderson bought 562 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were acquired at an average price of GBX 1,278 ($17.92) per share, for a total transaction of £7,182.36 ($10,070.61). Also, insider Patrick Vallance sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.37), for a total value of £262,000 ($367,358.38). Over the last three months, insiders acquired 581 shares of company stock worth $743,284.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.